potassium chloride 8 MEQ Extended Release Oral Tablet
potassium chloride
RxCUI: 312529
What the CMS Formulary Data Shows for potassium chloride 8 MEQ Extended Release Oral Tablet
Per the CMS 2026 Part D formulary file, potassium chloride 8 MEQ Extended Release Oral Tablet (RxNorm concept RXCUI 312529, generic name potassium chloride) appears on 330 distinct formulary files spanning 5,067 Medicare Part D plan offerings - 100% of enrollable Part D products, near-universal placement. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 1.6.
Real-world access to potassium chloride 8 MEQ Extended Release Oral Tablet depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 3,479,756 Part D beneficiaries filled potassium chloride 8 MEQ Extended Release Oral Tablet in 2023, with total plan-and-beneficiary spending of $396,202,925 and an average per-beneficiary annual cost of $113.86. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry potassium chloride 8 MEQ Extended Release Oral Tablet today.
Coverage Details
- Formularies covering
- 330
- Plans covering
- 5,067
- Coverage rate
- 100%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 2, Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 3,479,756
- Total spending
- $396,202,925
- Avg per beneficiary
- $113.86
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering potassium chloride 8 MEQ Extended Release Oral Tablet
100 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is potassium chloride 8 MEQ Extended Release Oral Tablet covered by Medicare Part D?
Yes, potassium chloride 8 MEQ Extended Release Oral Tablet is covered by 5,067 Medicare Part D plans (100% of all Part D formularies).
What tier is potassium chloride 8 MEQ Extended Release Oral Tablet on Medicare Part D plans?
potassium chloride 8 MEQ Extended Release Oral Tablet averages Tier 1.6 across Part D plans, ranging from Tier 1 to Tier 4.
Does potassium chloride 8 MEQ Extended Release Oral Tablet require prior authorization?
0% of Part D formularies require prior authorization for potassium chloride 8 MEQ Extended Release Oral Tablet. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on potassium chloride 8 MEQ Extended Release Oral Tablet?
In 2023, total Medicare Part D spending on potassium chloride 8 MEQ Extended Release Oral Tablet was $396,202,925, covering 3,479,756 beneficiaries. The average spend per beneficiary was $113.86.
Read our methodology - how this data is sourced, computed, and verified.